277 related articles for article (PubMed ID: 26105207)
1. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
2. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
4. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
Stettner MR; Wang W; Nabors LB; Bharara S; Flynn DC; Grammer JR; Gillespie GY; Gladson CL
Cancer Res; 2005 Jul; 65(13):5535-43. PubMed ID: 15994925
[TBL] [Abstract][Full Text] [Related]
5. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
6. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
[TBL] [Abstract][Full Text] [Related]
7. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
Je DW; O YM; Ji YG; Cho Y; Lee DH
Pancreas; 2014 Jul; 43(5):768-76. PubMed ID: 24763074
[TBL] [Abstract][Full Text] [Related]
10. The role of Src family kinases in growth and migration of glioma stem cells.
Han X; Zhang W; Yang X; Wheeler CG; Langford CP; Wu L; Filippova N; Friedman GK; Ding Q; Fathallah-Shaykh HM; Gillespie GY; Nabors LB
Int J Oncol; 2014 Jul; 45(1):302-10. PubMed ID: 24819299
[TBL] [Abstract][Full Text] [Related]
11. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.
Tabariès S; Annis MG; Hsu BE; Tam CE; Savage P; Park M; Siegel PM
Oncotarget; 2015 Apr; 6(11):9476-87. PubMed ID: 25823815
[TBL] [Abstract][Full Text] [Related]
12. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Roseweir AK; Qayyum T; Lim Z; Hammond R; MacDonald AI; Fraser S; Oades GM; Aitchison M; Jones RJ; Edwards J
BMC Cancer; 2016 Mar; 16():229. PubMed ID: 26984511
[TBL] [Abstract][Full Text] [Related]
13. Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy.
Liu WM; Huang P; Kar N; Burgett M; Muller-Greven G; Nowacki AS; Distelhorst CW; Lathia JD; Rich JN; Kappes JC; Gladson CL
PLoS One; 2013; 8(8):e70804. PubMed ID: 23936469
[TBL] [Abstract][Full Text] [Related]
14. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases.
Mohammed S; Shamseddine AA; Newcomb B; Chavez RS; Panzner TD; Lee AH; Canals D; Okeoma CM; Clarke CJ; Hannun YA
Breast Cancer Res; 2021 Jul; 23(1):76. PubMed ID: 34315513
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.
Dhruv HD; Whitsett TG; Jameson NM; Patel F; Winkles JA; Berens ME; Tran NL
Carcinogenesis; 2014 Jan; 35(1):218-26. PubMed ID: 23975833
[TBL] [Abstract][Full Text] [Related]
16. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
de Groot J; Milano V
J Neurooncol; 2009 Nov; 95(2):151-163. PubMed ID: 19436954
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Feng H; Hu B; Jarzynka MJ; Li Y; Keezer S; Johns TG; Tang CK; Hamilton RL; Vuori K; Nishikawa R; Sarkaria JN; Fenton T; Cheng T; Furnari FB; Cavenee WK; Cheng SY
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3018-23. PubMed ID: 22323579
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
19. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.
Huveldt D; Lewis-Tuffin LJ; Carlson BL; Schroeder MA; Rodriguez F; Giannini C; Galanis E; Sarkaria JN; Anastasiadis PZ
PLoS One; 2013; 8(2):e56505. PubMed ID: 23457577
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]